Apc (adenomatous polyposis coli) encodes a tumour suppressor gene that is mutated in the majority of colorectal cancers. Recent evidence has also implicated Apc mutations in the aetiology of breast tumours. Apc is a component of the canonical Wnt signal transduction pathway, of which one target is Tcf-1. In the mouse, mutations of both Apc and Tcf-1 have been implicated in mammary tumorigenesis. We have conditionally inactivated Apc in both the presence and absence of Tcf-1 to examine the function of these genes in both normal and neoplastic development. Mice harbouring mammaryspecific mutations in Apc show markedly delayed development of the mammary ductal network. During lactation, the mice develop multiple metaplastic growths which, surprisingly, do not spontaneously progress to neoplasia up to a year following their induction. However, additional deficiency of Tcf-1 completely blocks normal mammary development and results in acanthoma.
Introduction
The tumour suppressor gene adenomatous polyposis coli (Apc) was first identified in the dominantly inherited disorder familial adenomatous polyposis (FAP) (Groden et al., 1991) . This is characterized by the development of multiple colorectal adenomas some of which progress to carcinoma. It is now clear that Apc is mutated in the vast majority of colorectal cancers, both spontaneous and inherited (Fearnhead et al., 2001) . Apc encodes a very large protein of 2843 amino acids. Our understanding of the mechanisms by which loss of Apc function leads to colon cancer is far from complete. However, it is clear that one of the functions of Apc lies in its regulation of the Wnt signalling pathway. Wnts are secretory glycoproteins that have important roles in the development of many tissues (Cadigan and Nusse, 1997) . Activation of the canonical Wnt signalling pathway leads to the stabilisation of bcatenin, a multifunctional protein normally found in adherens junctions. Apc forms part of a complex which normally targets cytoplasmic b-catenin for degradation by the proteasome (Fearnhead et al., 2001; Polakis, 2000) . In response to Wnt signals, stabilized cytoplasmic b-catenin translocates to the nucleus where it interacts with members of the LEF/TCF family of transcription factors . Many Apc mutations associated with neoplasia give rise to a form of the protein unable to target b-catenin for ubiquitination and degradation, resulting in accumulation of nuclear b-catenin. It is now commonly accepted that the key tumour suppressor function of Apc lies in its ability to destabilize free b-catenin (Smits et al., 1999; Bienz and Clevers, 2000) . A number of genes activated by this pathway have been identified, including cyclin D1 (Tetsu and McCormick, 1999; Shtutman et al., 1999) , c-myc (He et al., 1998) , PPARd (He et al., 1999) and Tcf-1 . Cyclin D1 has recently been shown to be central to ras and neu mediated mammary oncogenesis, although this despondency apparently does not extend to pathways driven by c-myc or Wnt1 (Yu et al., 2001) . TCF functions often depend on partner proteins and on simultaneous signalling by other pathways. Thus, TCF is believed to play a key role in integrating multiple positional inputs (Bienz and Clevers, 2000) . The activation of Tcf-1 by b-catenin/Tcf-4 acts within a feedback repressor pathway, whereby Tcf-1 isoforms lacking a b-catenin interaction domain bind to DNA target sequences but fail to mediate gene activation. Negative regulation by Tcf-1 may also involve Groucho-related transcriptional repressors, as Tcf-1 has been shown to interact with Groucho proteins in Xenopus (Roose et al., 1998 .
Overexpression of Wnt1, Wnt3 and Wnt10B genes in the mammary epithelium promotes tumorigenesis (Nusse and Varmus, 1982; Tsukamoto et al., 1988; Lane and Leder, 1997) ; and stabilization of cytoplasmic b-catenin is critical for Wnt-mediated oncogenicity (Shimizu et al., 1997) . It has recently been shown by two groups that mice overexpressing a mutant, stabilized form of b-catenin in the mammary gland also develop tumours (Imbert et al., 2001; Michaelson and Leder, 2001) , although other workers have reported that conditional mutation of b-catenin can lead to metaplasia, rather than neoplasia (Miyoshi et al., 2002) .
Mice deficient in Tcf-1 are viable and capable of lactation, but acanthomas are reported to develop in the females, with an earliest onset of 4 months and with a peak incidence of 25% at 12 months of age . Synergy has already been demonstrated between mutations in Tcf-1 and Apc through accelerated tumorigenesis on the Apc Min heterozygous background .
Although Wnt1 overexpression leads to tumour development, Wnt1 itself is not normally expressed in the mammary gland, suggesting that ectopically expressed Wnt mediates its effect through receptors for other Wnts that are normally expressed there. A number of Wnts are expressed in dynamic patterns in the mammary gland and some of these have been shown to affect its normal development (Bradbury et al., 1995; Brisken et al., 2000) .
In the last few years, strong evidence of a link between Apc mutation and human breast cancer has begun to accumulate. First, loss of heterozygosity at 5q21 (the chromosomal location of human Apc) has been observed in sporadic tumours of the breast (Kashiwaba et al., 1994; Thompson et al., 1993) . Second, lost or reduced Apc protein expression has been demonstrated in human breast cancers (Ho et al., 1999; Schlosshauer et al., 2000) . Third, the Apc I1307K polymorphism has been shown to increase the risk of breast cancer in association with BRCA founder mutations (Woodage et al., 1998) . Fourth, a recent study has demonstrated the presence of somatic Apc mutations in 18% of primary breast cancers of a range of histological types (Furuuchi et al., 2000) . Interestingly, the mutations reported by Furuuchi et al. (2000) are scattered throughout the Apc coding region and not confined to the mutation cluster region (MCR) defined by Apc mutations found in colon tumours. Finally, it has now been shown that the Apc promoter is frequently hypermethylated in breast cancers (Jin et al., 2001) . Of note, this study was performed over a range of histological classes of primary breast cancer, with no clear association reported between histological type and methylation status.
Mice homozygous for inactivating mutations in Apc (such as Apc Min ) die at an early embryonic stage (Moser et al., 1995) . Heterozygous mice are viable, but prone to the development of intestinal adenomas and mammary carcinomas (Moser et al., 1993) . Homozygous lethality therefore precludes the direct analysis of the developmental role of Apc in adult organ systems. In order to analyse the role of Apc both in the development of the mammary gland and in mammary tumorigenesis, we have used a cre-loxP based strategy (Gu et al., 1994) to conditionally inactivate Apc. We have also investigated the interaction between Apc and Tcf-1 deficiency by subsequently crossing onto a Tcf-1 null background. Here we report that deficiency of Apc perturbs development and leads to metaplasia, and that combined deficiency of Apc and Tcf-1 blocks normal mammary gland development and results directly in acanthoma formation.
Results

Mammary gland specific inactivation of Apc
Mice homozygous for a loxP-flanked ('floxed') exon 14 Apc have previously been shown to develop normally. These were designated Apc 580s/580s , where 's' denotes silent mutation. Cre-mediated excision of the floxed exon 14 leads to a frameshift mutation at codon 580, in the region of the armadillo repeats. These mice developed adenomas within 4 weeks when cre recombinase was introduced to the colorectal region via infection with an adenovirus encoding the recombinase (Shibata et al., 1997) . To examine the role played by Apc in mammary gland development we used a transgenic approach where the cre gene is under the control of the ovine b-lactoglobulin enhancer (BLG-cre). This transgene has previously been shown to induce very efficient excision of floxed DNA molecules in mice (Selbert et al., 1998; Chapman et al., 1999) .
We generated mice homozygous for the floxed Apc allele (Apc 580s/580s ) and carrying the BLG-cre transgene. All mice so far generated have developed normally with litter sizes being similar between cre + Apc 580s/580s , cre + Apc 580s/+ and cre 7 Apc 580s/580s females. Numbers of male and female offspring have shown no bias towards either sex from control versus experimental strains. However, it was noted that offspring from the cre + Apc 580s/580s mothers did not thrive. As a sensitive measure of cre recombinase activity in the epithelium of virgin glands, we crossed our BLGcre transgenic animals to the cre ROSA reporter strain (Soriano, 1999) . Virgin mammary glands were removed from double transgenics and stained for b-galactosidase activity (Figure 1 ). Wholemount and histological analysis of these glands showed widespread and highly efficient recombination throughout the epithelium of the virgin gland. By day 10 of lactation the level of recombination as scored by the reporter strain rose to nearly 100% of epithelial cells (Figure 1 ). This analysis reflects the efficiency of cre mediated recombination at a single lox flanked allele.
Despite the very high levels of recombination indicated by the reporter strain and previous high levels of recombination obtained at other loci using this strain (Chapman et al., 1999; Selbert et al., 1998) , densitometric analysis of Southern blots showed only approximately 30% of entire mammary gland DNA from cre + . Apc 580s/580s had undergone cre mediated recombination at day 10 of lactation (unpublished data). This reduced level of recombination may reflect relatively inefficient recombination at the Apc allele, the requirement for two recombination events within each cell or the effect of inclusion of non-epithelial cells (Southern analysis was performed on entire mammary glands, inclusive of lymph nodes). If, indeed, the low level of recombination directly reflects low efficiency recombination, this would predict a high incidence of heterozygous Apc mutant cells within the gland, and rather small numbers of homozygous mutant cells. We favour a second possibility, namely that of efficient recombination at the Apc allele, but subsequent strong selection against the recombined cells during mammary gland development, possibly mediated by apoptotic deletion of the recombined cells. We are currently investigating this possibility within our model.
Apc is required in virgin mammary gland
To investigate any potential role for Apc in the virgin gland, we examined wholemount mammary gland preparations from virgin animals. The extent of ductal growth of mammary glands from cre + Apc 580s/580s mice was markedly delayed when compared with littermate control genotypes (Figure 2 ), consistent with a role for Apc in the normal growth of the gland. Although delayed in development, mutant glands appeared otherwise normal, showing neither the increased branching observed in MMTV-Wnt1 transgenic mice (Tsukamoto et al., 1988; Imbert et al., 2001) or the precocious lobulo-alveolar development seen in MMTV-DN89b-catenin mice (Imbert et al., 2001) .
Loss of Apc leads to mammary gland metaplasia
We next analysed the consequence of Apc disruption during lactation. Histological examination of day 10 lactating mammary glands from cre + Apc 580s/580s mice revealed extensive metaplastic nodules throughout each mammary gland examined. This phenotype was 100% penetrant, being observed in all glands in all mice examined. The nodules consist of tightly bound balls of epithelial cells emanating from ducts, which transdifferentiate into squamous cells ( Figure  3f ). Small areas of similar appearance were found in virgin mammary sections ( Figure 3b ). Immunohistochemistry was performed to confirm that these areas arose following loss of Apc function using a c- terminal Apc antibody. This analysis confirmed loss of Apc specifically within the tightly bound balls of epithelial cells (see Figure 6g ,h) Ductal structures in mutant mammary glands appeared disorganized and papillary growth occurs into ducts (Figure 3g ). Figure 3h shows a section of normal ductal epithelium with a secretory lobule apparently developing from it that shows prominent squamous metaplasia. We observed keratohyaline granules, the hallmark of keratinizing squamous differentiation (Figure 4a ), although more often we noted an eosinophilic material deriving from non-keratinizing squamous differentiation (Figures 3f and 4c ). This material was frequently seen to form areas which contained no nuclei, but which were characterized by open spaces (Figure 4c ). 
Apc
580s/+ animals (a,c,e,g,i) and cre + Apc 580s/580s littermates (b,d,f,h,j). Growth of the ductal network initiates at the nipple end of the mammary fat pad (left) and progresses past the lymph node (LN) to completely fill the pad. The tip of the growing ductal network is marked by an arrow. Virgin glands shown are 4 weeks (a,b), 6 weeks (c,d), 8 weeks (e,f) and 12 weeks (g,h). (i) shows a 70 day control mammary at parturition and (j) shows a 70 day experimental mammary at parturition. Note that at this time point, despite the mammary having developed lobular alveolar structures, ductal growth has failed to reach the end of the fat pad. Analyses of older cre + Apc 580s/580s mice show that ductal growth does eventually succeed in reaching the end of the fat pad
The number of metaplastic nodules increased during lactation, with least evidence of the phenotype at parturition (Figure 3d ). By day 10 of lactation, multiple foci were apparent (Figure 3f ). To investigate if the mammary metaplasias would revert to normal tissue, we examined glands that had undergone postlactational involution. We found that the area of metaplasia remain after involution and increased in number and extent after two lactation cycles ( Figure  5 ), but that no progression to neoplasia occurred. Mice have been allowed to pass through up to four complete lactation cycles, however, we have not observed progression to neoplasia up to 1 year following the initial lactation cycle (n=10).
Characterization of the metaplastic lesions
In order to investigate whether the metaplastic areas were composed of cycling cells, we assessed which cells were in S phase by the use of BrdU labelling. In contrast to the acinar epithelial cells, the parabasal cells in the metaplastic units were frequently found to be cycling (Figure 6b ). Histological analysis revealed frequent apoptosis within areas associated with the maturing squamous cells, but not in the mature squamous epithelium (Figure 4b ). TUNEL analysis confirmed the presence of apoptosis, but also showed the mature squamous cells to be weakly TUNEL positive (Figure 4d ). This latter observation may reflect a process of anucleation within these cells, which To examine whether b-catenin is dysregulated in these metaplasias, we used immunohistochemistry to examine the localization of b-catenin in mammary tissue. The balls of metaplastic squamous epithelium stain strongly for b-catenin throughout the cell cytoplasm and nucleus (Figure 6d ), whereas normal mammary acinar epithelium stains only at the cell membrane where b-catenin is found in adherens junctions (Figure 6c) . Little or no expression of bcatenin was observed in the mature squamous epithelium (Figure 6b,d) . We analysed expression of cyclin D1 and c-myc, two of the putative target genes activated by the b-catenin-TCF/LEF pathway. We found increased levels of cyclin D1 could be detected in the balls of epithelial cells (Figure 6f ), but could not show upregulation of c-myc by immunohistochemistry (data not shown).
Synergy between the Apc 580s mutation and Tcf-1 deficiency Tcf-1 deficient mice have previously been reported to develop acanthoma, with earliest onset of 7 months and with approximately 15% penetrance by 12 months . This phenotype is accelerated on the Apc Min background, resulting in acanthoma development as early as 2 months of age . To address the extent of synergy between Apc and Tcf-1 in our model, we crossed the floxed Apc allele onto a Tcf-1 null background. Female mice which were BLG-cre positive and homozygous for both the floxed Apc allele and the null Tcf-1 allele were examined at between 3.5 weeks and 8 weeks of age (Figure 7) . At all ages no normal mammary epithelium was observed, with each gland in every mouse analysed (n=6) being replaced by adenoacanthoma. No tumours have been observed in age matched Tcf-1 +/+, Cre + Apc 580s/580s littermates derived from this cross. These results therefore show that absence of both genes absolutely blocks the normal programme of mammary development and directly results in acanthoma. The very rapid onset of neoplasia in the absence of both genes is particularly remarkable given the level of recombination reported by the lacZ reporter strain. This phenotype presumably reflects very rapid outgrowth from cells marked by early recombination.
Discussion
A role for Apc in virgin mammary gland
We have conditionally inactivated Apc in mammary epithelium and found that functional Apc is required for the normal growth of virgin mammary glands. Mutant glands grow more slowly than controls (Figure 2 ) but do ultimately reach the end of the fat pad. In driving cre expression from the promoter of a milk protein gene, we anticipated that the effects of cre-mediated Apc deletion would be found primarily (Figure 1) . Thus, the discovery of a phenotype in virgin gland is not wholly unexpected. Growth retardation is perhaps a surprising consequence of loss of Apc, as this is more commonly associated with increased cell proliferation (and indeed we demonstrate here increased proliferation in the absence of Apc -see Figure 6 ). One potential explanation of this apparent paradox comes from the observation that Apc binds cytoskeletal components -both the actin cytoskeleton and microtubules (Fearnhead et al., 2001) . Thus, disruption of the cytoskeleton in the absence of Apc could lead to a decreased ability of the tip of the growing duct to invade or grow through the fat pad. Consistent with this, Imbert et al. (2001) report a mild retardation in ductal extension in mice overexpressing DN89b-catenin, a mutant stabilized form of b-catenin lacking the N-terminal 89 amino acids -N-terminal deleted b-catenin has been suggested to interfere with Apc's ability to bundle microtubules at the tips of cell extensions (Nathke et al., 1996; Pollack et al., 1997) .
Several Wnt genes are expressed in the postnatal mammary gland, and these are thought to be involved in its morphogenesis. For example, Wnt4 acts downstream of the progesterone receptor to induce side-branching in the mammary epithelial ductal network during early pregnancy (Brisken et al., 2000) . Overexpression of certain Wnt genes or stabilized mutant b-catenin affects morphogenesis of the mammary ductal network. Mice overexpressing Wnt1 or Wnt10B in the mammary gland exhibit ductal hyperbranching and increased lobuloalveolar development (Tsukamoto et al., 1988; Lane and Leder, 1997) , whereas mammary expression of DN89b-catenin leads to inappropriate lobuloalveolar development in virgin glands (Imbert et al., 2001) . In our mice, loss of Apc leads to reduced ductal growth, but there are no comparable morphological effects to those described above (Figure 2 ). Possible explanations for these apparent discrepancies are discussed below.
Metaplasia as a consequence of loss of Apc
Cre + Apc 580s/580s animals develop numerous small areas of metaplasia in the ductal epithelium ( Figure  3b ). Pregnancy in these mice results in multiple metaplastic foci, none of which has so far progressed to neoplasia. Although we do not observe tumorigenesis, many of the histological features we report here resemble those observed in adenosquamous carcinomas, as defined by the Annapolis meeting (Cardiff et al., 2000) , however the multiple intraduct squamous papillomas reported here are novel. These results show that Apc controls the structural development and differentiation state of the gland, processes at least partly mediated through b-catenin and cyclin D1. We also show that additional loss of Tcf-1 transforms this phenotype by directly promoting acanthoma development, which strongly argues that Tcf-1 and Apc act in consort to maintain the normal differentiation programme.
Apc mutation is associated with mammary tumorigenesis in both human (Woodage et al., 1998; Furuuchi et al., 2000) and mouse (Moser et al., 1993) , most likely as a consequence of increased bcatenin stability. Hyperplasia and malignant transformation has previously been reported in mouse mammary epithelium when Wnt1, Wnt10B or truncated forms of b-catenin (both DN89 and DN90 mutants) are overexpressed (Tsukamoto et al., 1988; Edwards et al., 1992; Imbert et al., 2001; Michaelson and Leder, 2001) , again most likely as a result of increased b-catenin levels. This contrasts with the apparent failure to observe malignancy in the absence of Apc in our model (at least at high frequency considering the high number of Apc deficient cells present within the postlactational gland). There are subtle differences in the experimental paradigms that make direct comparisons difficult; however, in the single absence of Apc, although this leads to bcatenin stabilization (and accompanying high levels of cyclin D1) within areas of metaplasia, no tumours are seen. Thus, in both the virgin gland and during pregnancy and lactation, the effects of inactivating Apc appear to differ from the effects of ectopic Wnt signalling or overexpression of stabilized b-catenin. There are several possible explanations for these apparent differences. First, the transgenes may be expressed in different cell types. The adult mammary gland contains a population of stem cells that are able to give rise to complete, functional mammary glands (Kordon and Smith, 1998) and it has been suggested that MMTVinduced mammary tumours arise from infection of these stem cells (Callahan and Smith, 2000) . Thus, one possibility was that the BLG promoter was failing to drive deletion of the Apc gene within those stem cells that can give rise to tumours. Clearly, our results from the Tcf-1 intercross show that this is not the case, as the BLG promoter is clearly driving loss of Apc in cells which can be the founders of tumours.
Second, levels of b-catenin may be critical. Different levels of b-catenin might determine whether mammary ductal development proceeds normally, or whether hyperbranching or precocious lobuloalveolar development occurs instead. Further, there may be a threshold level of b-catenin above which tumorigenesis is triggered. This explanation fits well with the reported failure to observe tumorigenesis following cre mediated mutation of b-catenin (Miyoshi et al., 2002) , as this model does not rely on over expression of mutant bcatenin. In our model, one might argue that single deficiency of either Apc or Tcf-1 is insufficient to result in complete deregulation of b-catenin levels, but that this occurs in the absence of both genes. Alternatively, transcriptional activity may be regulated by the ratio of b-catenin to Tcf-1. Both of these explanations imply that b-catenin levels are a critical determinant of activity. In contrast to this view, Imbert et al. (2001) have argued that b-catenin levels are not relevant, as both high and low-expressing lines of their MMTVDNb-catenin transgenic mice display the same phenotype, with low expressors showing a longer latency. However, given that expression of endogenous bcatenin is downregulated in these animals, and that even the low expressing line produces around threefold more b-catenin from the transgene than the endogenous locus, it is difficult to draw clear conclusions about b-catenin levels from these experiments.
Third, mutant forms of b-catenin may have different properties to wild type b-catenin. As described above, MMTV-DNb-catenin transgenic mice develop mammary adenocarcinomas (Imbert et al., 2001; Michaelson and Leder, 2001) b-catenin has a cluster of putative phosphorylation sites for GSK3b in its amino terminal region. Phosphorylation at these sites results in targeting of the protein for proteasomal degradation. Deletion of the amino-terminal 89 amino acids of b-catenin results in the loss of these sites, thereby generating a stable mutant protein. However, deletion of either the 89 or 90 N-terminal amino acids may affect more than b-catenin stability. Guger and Gumbiner (2000) have shown that amino acid alterations at the amino terminus of b-catenin affect signalling independent of any effect on b-catenin levels. Furthermore, b-catenin is thought to be required for the formation of a stable complex between the nemolike kinase (NLK) and TCF/LEF (Ishitani et al., 1999) . The effects of both DN90 b-catenin DN89 b-catenin overexpression could be due to disruption of such an interaction. This hypothesis fits well with our observed synergy between the Tcf-1 and Apc mutations.
Fourth, it is well recognized that susceptibility to mammary hyperplasias and carcinomas in Apc min/+ mice is influenced by genetic background (Moser et al., 2001) . However, our animals are on a mixed genetic background, and therefore our failure to observe neoplasia is unlikely to be a reflection of a single resistant background. Furthermore, the dramatic increase in spontaneous tumorigenesis in the additional absence of Tcf-1 demonstrates that the background we are using is permissive for tumorigenesis.
Finally, the nature of the mutation at the Apc allele may determine final phenotype. There are phenotypic differences among the different Apc alleles described to date. Cre-mediated deletion of Apc 580s in colonic epithelium leads to the efficient formation of adenocarcinomas (Shibata et al., 1997) . However, we find no (or very low penetrance) tumorigenesis when the same mutation is specifically targeted to the mammary gland, although mutation of Apc in the context of Tcf-1 deficiency does directly lead to neoplasia. Thus mammary and colonic epithelia appear to respond differently following Apc mutation. Perhaps the mammary epithelium requires higher levels of b-catenin for malignant transformation, or perhaps some Apcindependent method of b-catenin regulation (such as by feedback repression by Tcf-1) is found in the mammary gland. Mutations in different parts of the Apc protein can give rise to different phenotypes, however, in this case the same allele (Apc 580s ) appears to have different effects in different tissues.
We observe increased expression of cyclin D1, a putative target of b-catenin in mutant glands. Studies of human breast cancer have reported that b-catenin mediates upregulation of cyclin D1 (Lin et al., 2000) , and that cyclin D1 expression is associated with metastasis (Buckholm et al., 2000) . Further, mice expressing cyclin D1 under the control of the MMTV LTR develop mammary adenocarcinomas (Wang et al., 1994) and cyclin D1 deficiency has been shown to block ras and neu mediated (but critically not Wnt mediated) mammary tumorigenesis. The implication from these studies is that elevated levels of cyclin D1 can be potent in driving neoplasia. In our model high levels of both b-catenin and cyclin D1 were observed, but these were clearly associated with metaplasia and not neoplasia. It will be of great interest to study the phenotype of the Apc and Tcf-1 mutants in the additional absence of cyclin D1.
In conclusion, we propose a model whereby loss of Apc within mammary epithelial cells leads to dysregulated growth, as a consequence of which cells adopt a transdifferentiation programme to non-cycling squamous epithelial cells. Dysregulation of b-catenin characterizes these areas of metaplasia. In the presence of functional Tcf-1, this process either fails to lead to neoplasia or does so at very low efficiency. In contrast, combined loss of Tcf-1 and Apc dramatically blocks normal mammary development and results in the direct formation of acanthoma. As we know that deficiency of Apc (from studies of the Apc Min mouse) can predispose to acanthoma these results therefore strongly implicate loss of Tcf-1 as a secondary event in this process. Investigation of the mechanism underlying these findings should yield valuable insights into the normal functions of Apc and Tcf-1 in the mammary gland, and also into their role in suppressing neoplasia within this tissue.
Materials and methods
Genotyping of mice
Detection of Apc and Tcf-1 alleles was carried out by PCR as previously described (Shibata et al., 1997; . The BLG-cre transgene was detected using the PCR also previously described (Selbert et al., 1998) . Mice were maintained on an outbred genetic background segregating for C57Bl/6, Ola129 and C3H genomes and therefore where direct comparisons were performed these were made between littermates.
Mammary gland wholemount
This procedure was carried out as described on the mammary gland website: http://mammary.nih.gov.
Tissue sections and immunohistochemistry
Five mm sections were cut from paraffin embedded tissue retrieved at necropsy. For control tissue, lung, liver, pancreas, salivary gland, spleen and kidney were taken. Control tissues were stained with haematoxylin and eosin and examined, no dysregulated growth or histological abnormalities were found. Immunohistochemistry was carried out using the DAKO EnVision plus system (cat. no. K4006) following the manufacturer's instructions. Animals were injected with BrdU (70 mg/g in sterile saline, i.p.) 2 h before sacrifice. Detection of BrdU incorporation was by antibody (Roche). Apc was detected using a c-terminus antibody (Midgeley et al., 1997) at a dilution of 1/100. Antigen retrieval was by microwaving in 10 mM citrate pH 6 for 263 min. b-catenin was detected using a mouse monoclonal antibody supplied by Transduction Laboratories (cat. no. C19220), used at 1/50 dilution. Antigen retrieval was by microwaving in 10 mM citrate buffer, pH 6.0 for 365 min. Cyclin D1 was detected using the mouse monoclonal DCS-6 (Nova Castra) at a dilution of 1/100. High pH Target Retrieval Solution (Dako, cat. no. S3308) was used for antigen retrieval, following the manufacturer's instructions. Tunel staining was carried out using the ApopTag Peroxidase in situ apoptosis detection kit (Intergen) following manufacturer's instructions.
lacZ staining
The protocol was adapted from that described by Brisken et al. (1998) . Mammary glands were removed, spread in a histocassette and fixed for 2 h in ice-cold 4% paraformaldehyde in PBS. Glands were then rinsed in (2 mM MgCl 2 , 0.1% sodium deoxycholate, 0.2% NP40 in PBS) at room temperature for 3630 min and stained overnight at 378C without agitation in the dark in X-gal staining buffer (1 mg/ ml X-gal, 5 mM K-ferricyanide, 5 mM K-ferrocyanide in rinse buffer). Glands were rinsed gently in PBS for 30 min at room temperature, dehydrated through 70, 95 and 100% ethanol (30 min each), cleared in BABB (2 : 1 ratio of benzyl alcohol : benzyl benzoate) and mounted in DPX medium prior to photography. For sections, this material was then embedded in paraffin and sectioned as normal. Sections were counterstained with 1% eosin, dehydrated through 70, 95 and 100% ethanol, cleared briefly in xylene and mounted in DPX mounting medium.
